Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents

被引:160
|
作者
Zangari, Maurizio
Fink, Louis M.
Elice, Francesca
Zhan, Fenghuang
Adcock, Dorothy M.
Tricot, Guido J.
机构
[1] Univ Utah, Div Hematol, Blood Marrow Transplant & Myeloma Program, Salt Lake City, UT USA
[2] Nevada Canc Inst, Lab Med, Las Vegas, NV USA
[3] St Bortolo Hosp, Vicenza, Italy
[4] Esoterix, Aurora, CO USA
关键词
PHASE-II TRIAL; METASTATIC COLORECTAL-CANCER; ACTIVATED PROTEIN-C; LENALIDOMIDE PLUS DEXAMETHASONE; DIAGNOSED MULTIPLE-MYELOMA; ENDOTHELIAL GROWTH-FACTOR; MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; V-LEIDEN MUTATION; VENOUS THROMBOEMBOLISM;
D O I
10.1200/JCO.2009.22.3875
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor-associated neoangiogenesis has recently become a suitable target for antineoplastic drug development. In this overview, we discuss specific drug-associated hemostatic complications, the already known pathogenetic mechanisms involved, and the effect of varying antithrombotic strategies. Multiple agents with angiogenic inhibitory capacity ( thalidomide, lenalidomide, bevacizumab, sunitinib, sorafenib, and sirolimus) have obtained US Food and Drug Administration approval, and many others have entered clinical trials. Arterial and venous thromboembolism and hemorrhage have emerged as significant toxicities associated with the use of angiogenesis inhibitors. We present a detailed analysis of the literature on thrombotic complication of antiangiogenic drugs. Close attention to hemostatic complications during antiangiogenic treatment is warranted. Further studies are required to better understand the pathophysiologic mechanisms involved and to define a safe prophylactic strategy.
引用
收藏
页码:4865 / 4873
页数:9
相关论文
共 50 条
  • [21] Engineered nanoparticles: thrombotic events in cancer
    Abdalla, Ahmed M. E.
    Xiao, Lin
    Ouyang, Chenxi
    Yang, Guang
    NANOSCALE, 2014, 6 (23) : 14141 - 14152
  • [22] Thrombotic Microangiopathy with Targeted Cancer Agents
    Blake-Haskins, John A.
    Lechleider, Robert J.
    Kreitman, Robert J.
    CLINICAL CANCER RESEARCH, 2011, 17 (18) : 5858 - 5866
  • [23] Nanoparticles as novel antiangiogenesis agents
    Perera, Vindya S.
    Yang, Liu D.
    Wu, Haiwa
    Fraizer, Gail C.
    Huang, Songping D.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
  • [24] Dosing Considerations for Obese Patients Receiving Cancer Chemotherapeutic Agents
    Hall, Ronald G., II
    Jean, Gary W.
    Sigler, Meredith
    Shah, Sachin
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (12) : 1666 - 1674
  • [25] Pulmonary cavitation in patients with thyroid cancer receiving antiangiogenic agents
    Datar, Saumil
    Cabanillas, Maria
    Dadu, Ramona
    Ost, David
    Grosu, Horiana B.
    BMC CANCER, 2020, 20 (01)
  • [26] Pulmonary cavitation in patients with thyroid cancer receiving antiangiogenic agents
    Saumil Datar
    Maria Cabanillas
    Ramona Dadu
    David Ost
    Horiana B. Grosu
    BMC Cancer, 20
  • [27] The risks of thrombotic and bleeding events in patients receiving PEGylated asparaginase for treatment of acute lymphoblastic leukemia.
    Mautner, Ben
    Pierce, Eric
    Mort, Joseph
    DiBenedetto, Samantha
    Wells, Leah
    Ghamsari, Farid
    Morse, Emily
    Morris, Amy
    Keng, Michael Kenneth
    El Chaer, Firas
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E19015 - E19015
  • [28] Thrombotic events among patients with AIDs
    Majluf-Cruz, A
    Luna-Castaños, G
    Nieto-Cisneros, L
    THROMBOSIS AND HAEMOSTASIS, 1999, : 82 - 82
  • [29] Anti-Thrombotic Therapy for Ambulatory Patients with Multiple Myeloma Receiving Immunomodulatory Agents: A Systematic Review
    Matar, Charbel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S445 - S445
  • [30] Thrombotic events in patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab
    Al-Shamsi, Humaid O.
    Anjum, Mahraz
    Al Farsi, Abdulaziz
    Shen, Hua
    Linkins, Lori-Ann
    Cook, Richard J.
    Major, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)